Cover Image

Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod

Jorge Correale,1 Erwin Chiquete,2 Alexey Boyko,3 Roy G Beran,4–6 Jorge Barahona Strauch,7,8 Snezana Milojevic,9 Nadina Frider101Department of Neurology, Raúl Carrea Institute for Neurological Research, Foundation for the Fight against Infant Neurological Illnesses (FLENI), Bueno...

Full description

Saved in:

Bibliographic Details
Main Authors:	Correale J (Author), Chiquete E (Author), Boyko A (Author), Beran RG (Author), Strauch JB (Author), Milojevic S (Author), Frider N (Author)
Format:	Book
Published:	Dove Medical Press, 2016-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod
by: Correale J, et al.
Published: (2014)

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
by: Pablo Bascuñana, et al.
Published: (2020)

CRITICAL APPRAISAL OF EFFECTIVENESS OF ORAL FINGOLIMOD ON RELAPSING MULTIPLE SCLEROSIS
by: Rizaldy Taslim Pinzon, et al.
Published: (2017)

Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis
by: Stanley Cohan MD, PhD, et al.
Published: (2015)

Advances in the treatment of relapsing–remitting multiple sclerosis – critical appraisal of fingolimod
by: Gasperini C, et al.
Published: (2013)

Substandard and/or counterfeit medicines for patients
by: Subhash C Arya, et al.
Published: (2007)

Substandard and Falsified Medicines in Myanmar
by: Mirai Sakuda, et al.
Published: (2020)

Generalized and patch granuloma annulare in a patient with psoriasis and multiple sclerosis after treatment with fingolimod
by: Funda Tamer, et al.
Published: (2024)

Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations
by: Ayzenberg I, et al.
Published: (2016)

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
by: Rozita Doosti, et al.
Published: (2021)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis
by: Martin Vališ, et al.
Published: (2023)

Improving Outcomes and Resource Use in Multiple Sclerosis: What are the Benefits Associated With an Early Treatment Strategy With Fingolimod?
by: João Carrasco, et al.
Published: (2016)

Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis
by: Jagadeswara Rao Earla, et al.
Published: (2021)

Fingolimod: The first oral drug approved by food and drug administration; A breakthrough in treatment of multiple sclerosis
by: Manish Singh, et al.
Published: (2011)

International nonproprietary names for monoclonal antibodies: an evolving nomenclature system
by: Sofia S. Guimaraes Koch, et al.
Published: (2022)

Substandard and falsified medicine screening technologies
by: Lukas Roth, et al.
Published: (2019)

Interferon-beta increases plasma ceramides of specific chain length in multiple sclerosis patients, unlike fingolimod or natalizumab
by: Florian Ottenlinger, et al.
Published: (2016)

Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS)
by: Feng J, et al.
Published: (2019)

Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Xin Wu, et al.
Published: (2021)

Locomotor and histological changes in a cuprizone-induced animal model of multiple sclerosis: comparison between alpha-tocopherol and fingolimod
by: Nilesh Kumar Mitra, et al.
Published: (2022)

Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach
by: Gasperini C, et al.
Published: (2012)

Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis
by: Carnero Contentti E, et al.
Published: (2022)

Severe rebound disease activity after fingolimod withdrawal in a pregnant woman with multiple sclerosis managed with rituximab: A case study
by: Beatriz Canibaño, et al.
Published: (2020)

Recall of substandard medicines in Brazil during the period 2010-2018
by: Cristiani Lopes Capistrano Gonçalves Oliveira, et al.
Published: (2023)

Substandard, falsified and unregistered medicines in Latin America, 2017-2018
by: Robin Rojas-Cortés
Published: (2020)

Combating Substandard and Counterfeit Medicines by Securing the Pharmaceutical Supply Chain:
by: Phuong Chi Nam Sophie Le, et al.
Published: (2018)

Safety of generic fingolimod
by: O. M. Koval, et al.
Published: (2018)

Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance
by: Elizabeth Pisani, et al.
Published: (2021)

Combatting Substandard and Falsified Medicines: Public Awareness and Identification of Counterfeit Medications
by: Faris El-Dahiyat, et al.
Published: (2021)

Falsified and substandard medicines trafficking: A wakeup call for the African continent
by: Yusuf Hassan Wada, et al.
Published: (2022)

A systematic review of counterfeit and substandard medicines in field quality surveys
by: Alghannam AFA, et al.
Published: (2014)

Toxicidad hepática por fingolimod
by: juan sebastian theran leon, et al.
Published: (2024)

Th1Th17CM Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment
by: Bibiana Quirant-Sánchez, et al.
Published: (2019)

Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names
by: Ian Wilkinson, et al.
Published: (2022)

Reports of substandard medicines: a lexicographic analysis of the Brazilian Health Surveillance Report System
by: Mayra Bruna Fedalto, et al.
Published: (2021)

Pharmacopoeia boosts the fight against substandard drugs

Future Information Technology Tools for Fighting Substandard and Falsified Medicines in Low- and Middle-Income Countries
by: Huma Rasheed, et al.
Published: (2018)

Substandard Quality of the Antimicrobials Sold in the Street Markets in Haiti
by: Théodule Jean-Baptiste, et al.
Published: (2020)

Detecting substandard pharmaceuticals though spectral finger-printing
by: C. Salmon, et al.
Published: (2015)

A cross-sectional analysis of falsified, counterfeit and substandard medicines in a low-middle income country
by: Daariimaa Khurelbat, et al.
Published: (2020)